Xilio Therapeutics Investor Relations Material
Latest events
Study Update
Xilio Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Xilio Therapeutics Inc
Access all reports
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm focusing on discovering and developing tumor-activated immuno-oncology therapies. It focuses on creating treatments that are activated in the tumor environment, aiming to enhance the efficacy of immuno-oncology treatments while minimizing side effects. The company's portfolio includes a checkpoint inhibitor program with XTX101, an anti-CTLA-4 monoclonal antibody, alongside cytokine programs featuring XTX202 (a tumor-activated IL-2) and XTX301 (an engineered IL-12 molecule). The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Xilio Therapeutics Inc
Study Update
Xilio Therapeutics Inc
Study Update
Xilio Therapeutics Inc
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
XLO
Country
🇺🇸 United States